Answers are grounded in this paper and cite their sources.
Drug resistance tuberculosis is one of the challenging tasks that dictates the desperate need for the development of new antitubercular agents which operate via novel modes of action. Here, we are reporting on 4‐aminoquinazolines as M. tuberculosis N ‐acetylglucosamine‐1‐phosphate uridyltransferase (GlmU MTB ) inhibitors to overcome the problem of the MDR‐TB. Amongst the synthesized compounds, two of them were observed to be the effective compounds of the series (IC 50 =6.4 μM (H37Rv), MIC=25 μM (MDR‐TB) and IC 50 =2.9 μM (H37Rv), MIC=6.25 μM (MDR‐TB), respectively).
No takes yet. Share an insight, caveat, or question.
Patel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: